Physician profile
Adam Cutler
NPI 1235128059
$1,191.09
in general payments reported to CMS, 2019-2025
22 companies · $218 in 2025
The $218 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $56.98 · 2021: $51.23 · 2022: $191 · 2023: $241 · 2024: $248 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $171.80 | 2019-2024 | Gardasil 9, Vaxneuvance, Rotateq |
| Cranial Technologies, INC | $168.20 | 2020-2025 | Doc Band |
| Sanofi Pasteur INC. | $106.74 | 2023-2025 | |
| Pfizer INC. | $71.44 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $69.37 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $65.99 | 2025 | Qelbree |
| Ultragenyx Pharmaceutical INC. | $62.92 | 2019-2022 | |
| Sobi, INC | $62.38 | 2019-2023 | |
| Corium, LLC | $45.96 | 2022-2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $40.90 | 2024-2025 | |
| Abbvie INC. | $39.47 | 2019 | |
| Seqirus USA INC | $37.76 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Phadia US INC. | $37.23 | 2023-2024 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $35.87 | 2023-2024 | Flumist Quadrivalent |
| Tris Pharma INC | $32.44 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.72 | 2024-2025 | Bexsero, Rotarix, Penmenvy |
| Vertical Pharmaceuticals, LLC | $29.17 | 2019 | |
| Biogen, INC. | $22.49 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.94 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $16.17 | 2023 | Methylphenidate Hydrochloride |
| Takeda Pharmaceuticals U.S.A., INC. | $15.08 | 2019 | |
| Welch Allyn | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Cutler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.